Pyc Therapeutics Ltd has released a press release.
Lead Investigational Drug Demonstrates Key Improvement
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Half Year Accounts and Appendix 4D
- Progress US Clinical Stage Company and Corporate Objectives
- Quarterly Activities Report and Appendix 4C
- Visual Evidence of Lead Drugs Efficacy
- Review of Activities and Appendix 4C
Later from PYC Therapeutics
- March 2021 Quarterly Report and Cashflow
- Second Drug Program Progressing Towards Human Trials
- Retina Target Engagement Confirmed in Large Eye
- Successful Completion of Key Translational Milestone
- Quarterly Activities and Appendix 4C Cash Flow Report
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics